Side effects of systemic interferon-containing drugs

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Interferons (IFNs) are proteins from the group of cytokines that are in charge for the activation of the immune response. There are three types of IFNs. All of them are capable of expressing antiproliferative and antiviral activity, due to which tumor growth is suppressed, and immune system is regulated and normalized. IFN-α and IFN-β are most widely used in clinical practice. Current review highlights the side effects of all types of systemic IFNs used for patients with infectious and oncological diseases. Negative impact of IFN-α and IFN-β on human organ systems which includes the development of a wide range of disorders – vegetative asthenic, gastroenterological, etc., is considered in details. The article summarizes information on the risks of using systemic IFNs, which can help physicians in managing various groups of patients, taking into account all possible adverse events.

Full Text

Restricted Access

About the authors

Yulia V. Chervinets

Tver State Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: julia_chervinec@mail.ru
ORCID iD: 0000-0001-9209-7839

MD, Dr. Sci. (Medicine), professor, head of the Department of microbiology and virology with a course in immunology

Russian Federation, 170100, Tver, 4 Sovetskaya St.

Vsevolod S. Belyaev

Tver State Medical University of the Ministry of Healthcare of Russia

Email: seva.belyaev.99@mail.ru
ORCID iD: 0000-0002-7165-5077

MD, assistant at the Department of microbiology and virology with a course in immunology

Russian Federation, 170100, Tver, 4 Sovetskaya St.

Maria S. Yukhimets

Tver State Medical University of the Ministry of Healthcare of Russia

Email: seva.belyaev.99@mail.ru

3rd year student of the Faculty of general medicine

Russian Federation, 170100, Tver, 4 Sovetskaya St.

Anastasia A. Nasser

Tver State Medical University of the Ministry of Healthcare of Russia

Email: nastya2002nasser2002@gmail.com

3rd year student of the Faculty of general medicine

Russian Federation, 170100, Tver, 4 Sovetskaya St.

Albert S. Pogosyan

Tver State Medical University of the Ministry of Healthcare of Russia

Email: albert-pogosyan-2001@mail.ru

5th year student of the Faculty of dentistry

Russian Federation, 170100, Tver, 4 Sovetskaya St.

References

  1. Cao L., Zhang L., Zhang X. et al. Types of interferons and their expression in plant systems. J Interferon Cytokine Res. 2022; 42(2): 62–71. https://doi.org/10.1089/jir.2021.0148. PMID: 35171703.
  2. Castro L.S., Lobo G.S., Pereira P. et al. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation. Vaccines (Basel). 2021; 9(4): 328. https://doi.org/10.3390/vaccines9040328. PMID: 33915863. PMCID: PMC8065594.
  3. Forsyth C.J., Chan W.-H., Grigg A.P. et al. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. Intern Med J. 2019; 49(8): 948–54. https://doi.org/10.1111/imj.14154. PMID: 30411442.
  4. Yeh M.-L., Huang J.-F., Dai C.-Y. et al. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin Drug Metab Toxicol. 2019; 15(10): 779–85. https://doi.org/10.1080/17425255.2019.1678584. PMID: 31593639.
  5. Bhattacharya D., Aronsohn A., Price J., Lo Re V.; AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023: ciad319. https://doi.org/10.1093/cid/ciad319. PMID: 37229695.
  6. Smith J.R., Ariano R.E., Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med. 2010; 38(4 Suppl): e43–51. https://doi.org/10.1097/CCM.0b013e3181c85229. PMID: 19935416.
  7. Ascierto P.A., Chiarion-Sileni V., Muggiano A. et al. Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon. J Chemother. 2014; 26(4): 193–201. https://doi.org/10.1179/1973947813y.0000000154. PMID: 24621162.
  8. Stickel F., Helbling B., Heim M. et al. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat. 2012; 19(2): 77–87. https://doi.org/10.1111/j.1365-2893.2011.01527.x. PMID: 22239497.
  9. Ramos M.S., Mardegan M.C., Tirone N.R. The clinical use of type 1 interferon in gynecology. Eur J Gynaecol Oncol. 2010; 31(2): 145–50. PMID: 20527228.
  10. Sleijfer S., Bannink M., Van Gool A.R. et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005; 27(6): 423–31. https://doi.org/10.1007/s11096-005-1319-7. PMID: 16341948.
  11. Nachnani J.S., Rao G.A., Bulchandani D. et al. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol. 2010; 89(2): 121–25. https://doi.org/10.1007/s00277-009-0774-y. PMID: 19565241.
  12. Valentine A.D., Meyers C.A. Neurobehavioral effects of interferon therapy, current psychiatry reports. Curr Psychiatry Rep. 2005; 7(5): 391–95. https://doi.org/10.1007/s11920-005-0042-3. PMID: 16216160.
  13. Fragoso Y.D., Paggiaro M.S., Mastromauro R. et al. Literature systematic review on the ophthalmological side effects of interferons. Arq Bras Oftalmol. 2011; 74(4): 306–10. https://doi.org/10.1590/s0004-27492011000400017. PMID: 22068863.
  14. [Lapinski T.W., Prokopowicz D. The neuropsychiatric side effects of the interferon therapy in patients with chronic hepatitis B and C. Pol Merkur Lekarski. 1999; 7(37): 8–11 (In Polish)]. PMID: 10522402.
  15. Huckans M., Fuller B., Wheaton V. et al. A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res. 2015; 78(2): 184–92. https://doi.org/10.1016/j.jpsychores.2014.07.020. PMID: 25219976. PMCID: PMC4435678.
  16. Ingimarsson S., Cantell K., Strander H. Side effects of long-term treatment with human leukocyte interferon. J Infect Dis. 1979; 140(4): 560–63. https://doi.org/10.1093/infdis/140.4.560. PMID: 292735.
  17. Scott G.M. Interferon: Pharmacokinetics and toxicity. Philos Trans R Soc Lond B Biol Sci. 1982; 299(1094): 91–107. https://doi.org/10.1098/rstb.1982.0109. PMID: 6183699.
  18. Wu W., Metcalf J.P. The role of type I ifns in influenza: Antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020; 12(6): 437–47. https://doi.org/10.1159/000508379. PMID: 32564033. PMCID: PMC7747089.
  19. Flores-Robles B.J., Sangüesa-Gómez C.P., Mateos C.B. et al. Sarcoidosis developing after treatment with interferon alpha in a patient with hepatitis C: An association every physician should know. Rev Gastroenterol Mex. 2017; 82(2): 185–86. https://doi.org/10.1016/j.rgmx.2016.01.005. PMID: 27161792.
  20. Ortiz Salvador J.M., Victoria Martínez A.M., Ferrer D.S. et al. Interferon alfa-induced sarcoidosis resolving without drug withdrawal. JAAD Case Rep. 2016; 2(2): 146–49. https://doi.org/10.1016/j.jdcr.2016.02.003. PMID: 27222872. PMCID: PMC4864091.
  21. Chiang C.-H., Lai F.-J. Sarcoidosis on the injection sites following treatment of interferon-alpha and ribavirin for hepatitis C. J Formos Med Assoc. 2014; 113(12): 981–82. https://doi.org/10.1016/j.jfma.2014.07.008. PMID: 25187070.
  22. Bush A.E., Hymes S.R., Silapunt S. Lichenoid dermatitis prom interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV. J Drugs Dermatol. 2017; 16(7): 714–16. PMID: 28697228.
  23. Rahmani H., Davoudi-Monfared E., Nourian A. et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88: 106903. https://doi.org/10.1016/j.intimp.2020.106903. PMID: 32862111. PMCID: PMC7445008.
  24. Kavanagh D., McGlasson S., Jury A. et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016; 128(24): 2824–33. https://doi.org/10.1182/blood-2016-05-715987. PMID: 27663672. PMCID: PMC5159705.
  25. Reddy K.R. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis. 2004; 24 Suppl 2: 33–38. https://doi.org/10.1055/s-2004-832926. PMID: 15346244.
  26. Kang H.Y., Shin M.C. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012; 26(2): 147–50. https://doi.org/10.3341/kjo.2012.26.2.147. PMID: 22511844. PMCID: PMC3325622.
  27. Choi J.W., Lee J.S., Paik W.H. et al. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol. 2016; 22(1): 168–71. https://doi.org/10.3350/cmh.2016.22.1.168. PMID: 27044768. PMCID: PMC4825169.
  28. Song J.S., Sohn J.H., Jeong J.Y. et al. Repeated panniculitis induced by pegylated interferon alpha 2a in a patient with chronic hepatitis C. Korean J Gastroenterol. 2016; 67(5): 272–76. https://doi.org/10.4166/kjg.2016.67.5.272. PMID: 27206440.
  29. El-Dosouky I.I., Elhawari S., Emara M.H., Hamed E.F. Types and predictors of interferon/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus. Zagazig University Medical Journal. 2014; 20(5): 1–11. https://doi.org/10.21608/zumj.2014.4427.
  30. Xia C., Vijayan M., Pritzl C.J. et al. Hemagglutinin of influenza A virus antagonizes type I interferon (IFN) responses by inducing degradation of type I IFN receptor 1. J Virol. 2015; 90(5): 2403–17. https://doi.org/10.1128/JVI.02749-15. PMID: 26676772. PMCID: PMC4810695.
  31. Xia C., Wolf J.J., Vijayan M. et al. Casein kinase 1α mediates the degradation of receptors for type I and type II interferons caused by hemagglutinin of influenza A virus. J Virol. 2018; 92(7): e00006–18. https://doi.org/10.1128/JVI.00006-18. PMID: 29343571. PMCID: PMC5972889.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Side effects of pegylated interferon preparations [29]

Download (78KB)
Indexing metadata

Copyright (c) 2024 Bionika Media